Experience with tocilizumab, an interleukin 6 inhibitor, used for the treatment of giant cell arteritis with severe comorbidity
Бекетова Т. В., Ушакова М. А., Никишина Н. Y., Хелковскайа-Сергеева А. Н., Николаева Е. В., Сажина Е. Г., Новоселова Т. М., Насонов Е. Л.
Научно-практическая ревматология
Т. 56, Вып. 2, С. 228-234
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.14412/1995-4484-2018-228-234
Аннотация:
Giant cell arteritis (GCA), formerly known as Horton's disease, is among the most common diseases from a group of systemic vasculitides; its clinical significance is complemented with the potential involvement of the coronary arteries, aorta, and cranial arteries with development of ischemic optic neuropathy if there is no timely treatment that results in rapid and irreversible visual loss. The elderly age of patients is one of the key aspects of GCA. Therefore, the disease is often accompanied by various comorbidities that have considerable impact on the choice of a treatment regimen and limit the use of standard therapy with glucocorticoids (GCs). The complications due to GC treatment can be competitive in severity with GCA, especially in elderly multimorbid patients. Progress in rheumatology due to the introduction of biological agents (BAs) has created the preconditions for the development of a new area of pharmacotherapy for GCA associated with interleukin 6 (IL6) inhibition using
Ключевые слова:
Giant cell arteritis; Interleukin 6; Tocilizumab.
Язык текста: Русский
ISSN: 1995-4492
Бекетова Т. В. Татьяна Валентиновна 0001-
Ушакова М. А.
Никишина Н. Y. Н.Ю.
Хелковскайа-Сергеева А. Н.
Николаева Е. В.
Сажина Е. Г.
Новоселова Т. М.
Насонов Е. Л. Евгений Львович 1948-
Beketova T. V. Tat`yana Valentinovna 0001-
Ushakova M. A.
Nikishina N. Y. N.Yu.
Khelkovskaya-Sergeeva A. N.
Nikolaeva E. V.
Sazhina E. G.
Novoselova T. M.
Nasonov E. L. Evgenij L`vovich 1948-
Experience with tocilizumab, an interleukin 6 inhibitor, used for the treatment of giant cell arteritis with severe comorbidity
Текст визуальный непосредственный
Научно-практическая ревматология
ИМА-Пресс
Т. 56, Вып. 2 С. 228-234
2018
Статья
Giant cell arteritis Interleukin 6 Tocilizumab.
Giant cell arteritis (GCA), formerly known as Horton's disease, is among the most common diseases from a group of systemic vasculitides; its clinical significance is complemented with the potential involvement of the coronary arteries, aorta, and cranial arteries with development of ischemic optic neuropathy if there is no timely treatment that results in rapid and irreversible visual loss. The elderly age of patients is one of the key aspects of GCA. Therefore, the disease is often accompanied by various comorbidities that have considerable impact on the choice of a treatment regimen and limit the use of standard therapy with glucocorticoids (GCs). The complications due to GC treatment can be competitive in severity with GCA, especially in elderly multimorbid patients. Progress in rheumatology due to the introduction of biological agents (BAs) has created the preconditions for the development of a new area of pharmacotherapy for GCA associated with interleukin 6 (IL6) inhibition using